Lapatinib in the treatment of HER-2 overexpressing breast cancer

Journal of B.U.ON.

Volumn 16, Issue 3, 2011, Pages 393-399

  Vrdoljak, Eduard ^a   Boban, M ^a   Ban, M ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Breast cancer; HER 2; Lapatinib; Targeted therapy

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROGESTERONE RECEPTOR; RAF PROTEIN; RAS PROTEIN; TRASTUZUMAB;

ANOREXIA; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; LIVER DISEASE; META ANALYSIS (TOPIC); METASTASIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 80053977101     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Frampton JE. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 2009; 69: 2125-2148.
2. Parkin DM, Bray F, Ferlay Y et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther 2009; 26: 263-271.
4. Oakman C, Pestrin M, Zafarana E, Cantisani E, Di Leo A. Role of lapatinib in the first line treatment of patients with metastatic breast. Cancer Manag Res 2010; 2: 13-25.
5. Liao J, Gallas M, Pegram M, Slingerland J. Lapatinib: new opportunities for management of breast cancer. Breast Cancer: Targets and Therapy 2010; 2: 79-91.
6. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
7. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
8. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
10. Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 2005; 1059: 70-75. (Pubitemid 43211612)
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
12. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
13. Faneyte IF, Peterse JL, van TH et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004; 10: 4457-1463.
14. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
15. Leferink AE, Simpson JF, Shawver LK et al. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-a bigenic mice. Proc Natl Acad Sci USA 2000; 97: 9609-9614. (Pubitemid 30650823)
16. Spector NL, Xia W, Bums III H et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-2512. (Pubitemid 47050840)
17. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639. (Pubitemid 43259947)
18. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-6659.
19. Rusnak DW, Affleck K, Lackey K et al. The characterization of novel, dual ErbB-2/EGFR tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-7203. (Pubitemid 32946515)
20. Tykerb (Lapatinib, Package insert). Research Triangle Park, NC; GlaxoSmithKline: 2010.
21. Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008; 65: 1703-1710.
22. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-6263.
23. Versola M, Burris HA, Jones S et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol 2004; 14: abstr#3047.
24. Minami H, Nakagawa K, Kawada K et al. A phase I study of GW572016 in patients with solid tumors. J Clin Oncol 2004; 14: abstr#3048.
25. Burris HA, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313. (Pubitemid 46206984)
26. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743. (Pubitemid 46021510)
27. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
28. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-5552.
29. Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin Cancer Res 2006; 12: 1008-1012.
30. Leary AF, Drury S, Detre S et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010; 16: 1486-1497.
31. Chu QS, Cianfrocca ME, Goldstein LJ et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced breast cancer. Clin Cancer Res 2008; 14: 4484-4490.
32. Johnston S, Pippen Jr J, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
33. Finn RS, Press M, Dering J et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. J Clin Oncol 2009; 27: abstr#1018.
34. Sherril B, Sherif BN, Amonkar MM et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, HER2+ metastatic breast cancer (MBC). 2009 ASCO Breast Cancer Symposium: abstr #212.
35. Zembryki D, Gomez H, Koehler M et al. Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2009; 27: abstr#1095.
36. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
37. Gelmon KA, Parulekar W, Rappold E et al. COMPLETE: phase III study of taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer. 2009 ASCO Breast Cancer Symposium: abstr #247.
38. Baselga J, Bradbury I, Eidtmann H et al. First Results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX.
39. Untch M, Loibl S, Bischoff J et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GeparQuinto study (GBG 44). Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX.
40. Tykerb Evaluation After Chemotherapy (TEACH): lapatinib versus placebo in women with early-stage breast cancer. http://clinicaltrials.gov/ct2/show/ NCT00374322, accessed December 13, 2010.
41. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. http://clinicaltrials.gov/ct2/show/NCT00490139, accessed December 13, 2010.
42. Burstein HJ, Storniolo AM, Franco S et al. A phase II study of lapatinib monotherapy in chemotherapy refractory HER-2 positive or HER-2 negative advanced or metastatic breast cancer. Ann Oncol 2008; 19: 1068-1074. (Pubitemid 351796331)
43. Amir E, Ocana A, Seruga B, Freedman O, Clemons M. Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev 2010; 36: 410-415.